|
|
|
08/11/2010 7:01 AM
Valeant and Biovail Set Date for Shareholders Meetings
08/05/2010 7:04 AM
Biovail Reports Second-Quarter 2010 Financial Results
08/05/2010 6:59 AM
Biovail Declares Quarterly Dividend
07/23/2010 12:01 PM
Biovail Announces Second-Quarter 2010 Earnings Release, Conference-Call Details
06/22/2010 4:04 PM
Biovail and MedGenesis Announce Grant from The Michael J. Fox Foundation for the Development of GDNF
06/21/2010 2:37 AM
Valeant and Biovail Agree to Merge
06/03/2010 4:01 AM
Biovail Enters into License Agreement with Kyowa Hakko Kirin
05/06/2010 7:03 AM
Biovail Reports First-Quarter 2010 Financial Results
05/06/2010 6:58 AM
Biovail Announces Increase to Quarterly Dividend
04/22/2010 11:01 AM
Biovail Announces First-Quarter 2010 Earnings Release, Conference-Call Details
03/26/2010 7:02 AM
Biovail Acquires AMPAKINE(R) Compounds for Treatment of Respiratory Depression
02/25/2010 7:03 AM
Biovail Reports Fourth Quarter, Year-End 2009 Financial Results
02/25/2010 6:59 AM
Biovail Declares Quarterly Dividend
02/19/2010 3:55 PM
Biovail Comments on Filing of Complaints
02/12/2010 11:31 AM
Biovail Announces Fourth-Quarter 2009 Earnings Release, Conference-Call Details
02/10/2010 7:03 AM
Biovail Enters into License and Collaboration Agreement with Alexza for AZ-004
01/22/2010 3:02 PM
Biovail Comments on Proposed Generic Wellbutrin XL(R) Trial
01/06/2010 11:33 AM
Biovail to Present at JPMorgan Healthcare Conference
11/10/2009 1:58 PM
Biovail to Participate at Upcoming Conferences
11/05/2009 7:03 AM
Biovail Reports Third-Quarter 2009 Financial Results
11/05/2009 7:00 AM
Biovail Declares Quarterly Dividend
10/23/2009 10:01 AM
Biovail Announces Third-Quarter 2009 Earnings Release, Conference-Call Details
10/16/2009 2:36 PM
Biovail Receives 2009 Company of the Year Award from the Life Science Association of Manitoba
10/06/2009 7:01 AM
Biovail Provides Update on Pimavanserin Collaborative Development Program
09/10/2009 9:02 AM
Biovail to Participate at Upcoming Conferences
09/01/2009 6:00 AM
Biovail Announces Results from ACADIA's Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
08/24/2009 1:01 AM
Biovail to Acquire Rights to Develop, Commercialize JP-1730/Fipamezole in North America from Santhera
08/17/2009 7:01 AM
Biovail Comments on Ultram(R) ER Court Ruling
08/10/2009 4:31 PM
Biovail to Present at Canaccord Adams Global Growth Conference
08/06/2009 7:02 AM
Biovail Reports Second-Quarter 2009 Financial Results
08/06/2009 6:59 AM
Biovail Launches Share Repurchase Program
08/06/2009 6:56 AM
Biovail Declares Quarterly Dividend
07/28/2009 2:12 PM
Biovail Announces Second-Quarter 2009 Earnings Release, Conference-Call Details
06/22/2009 7:31 AM
Biovail Announces Closing of Acquisition of Worldwide Rights to Tetrabenazine
06/09/2009 5:21 PM
Biovail Announces New Increased Revolving Credit Facility
06/03/2009 7:48 PM
Biovail Announces Pricing of Offering of US$300 Million Senior Convertible Notes due 2014
06/02/2009 4:08 PM
Biovail Announces Offering of Senior Convertible Notes
05/29/2009 3:33 PM
Biovail to Participate at Upcoming Conferences
05/28/2009 12:31 PM
Biovail Announces Results of 2009 Annual and Special Meeting of Shareholders
05/26/2009 12:22 PM
Biovail Waives Deadline for Submitting Proxies
05/25/2009 9:02 PM
Biovail Announces Settlement of Proxy Contest
05/22/2009 8:45 AM
Biovail Advises Shareholders to Vote Their Blue Proxy Today
05/19/2009 8:02 AM
Biovail Announces That RiskMetrics, Glass Lewis and PROXY Governance All Recommend Voting the BLUE Proxy "FOR" Biovail's Director Nominees
05/18/2009 8:03 AM
Biovail Announces Acquisition of Worldwide Rights to Tetrabenazine
05/15/2009 3:14 PM
Biovail Receives 2009 Corporate Award from National Organization for Rare Disorders
05/15/2009 7:01 AM
Biovail Announces Termination of HSR Waiting Period, Closing of Acquisition of U.S. Rights to Wellbutrin XL(R)
05/14/2009 3:31 PM
Biovail Advises Shareholders to Use Their Blue Proxy to Reject Melnyk Nominees
05/11/2009 2:38 PM
Biovail to Participate at Upcoming Conferences
05/11/2009 10:36 AM
Biovail Announces Dismissal of Securities Litigation
05/06/2009 8:01 AM
ACADIA Pharmaceuticals and Biovail Announce Completion of Enrollment in First Pivotal Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
05/06/2009 7:04 AM
Biovail Reports First-Quarter 2009 Financial Results
05/06/2009 7:01 AM
Biovail Declares Quarterly Dividend, Announces Change in Dividend Policy
05/06/2009 5:01 AM
Biovail Announces Acquisition of U.S. Rights to Wellbutrin XL(R)
05/04/2009 7:32 AM
Biovail Enters into Collaboration and License Agreement with Acadia for Pimavanserin
05/01/2009 2:40 PM
Biovail Announces First-Quarter 2009 Earnings Release, Conference-Call Details
04/30/2009 4:10 PM
Biovail Issues Management Proxy Circular and Letter to Shareholders
04/21/2009 1:32 PM
Biovail Appoints Fred Nicklas Vice-President, U.S. Commercial Operations
04/07/2009 8:05 AM
Biovail Announces U.S. Availability of Aplenzin(TM) Tablets
04/06/2009 8:04 AM
Biovail Appoints Rochelle Seide Ph.D., J.D. Vice-President, Intellectual Property
03/27/2009 8:01 AM
Biovail Announces Establishment of External Advisory Board
03/17/2009 4:16 PM
Biovail Announces Annual and Special Meeting of Shareholders
03/09/2009 4:28 PM
Biovail to Present at Barclays Capital Global Healthcare Conference
02/26/2009 7:31 AM
Biovail Reports Fourth Quarter, Year-End 2008 Financial Results
02/26/2009 7:29 AM
Biovail Declares Quarterly Dividend
02/25/2009 3:16 PM
Biovail Receives Requisition from Dissident Shareholder Eugene Melnyk
02/12/2009 3:15 PM
Biovail Announces Fourth-Quarter 2008 Earnings Release, Conference-Call Details
01/09/2009 11:08 AM
Biovail Announces Approval of Settlement Agreement with OSC
01/07/2009 5:00 PM
Biovail Reaches Settlement Agreement with OSC Staff
12/30/2008 8:01 AM
Biovail Announces Voluntary Recall of Certain Lots of Ultram(R) ER 100mg Tablets
12/23/2008 4:06 PM
Biovail Announces Litigation Settlement
12/22/2008 8:01 AM
Biovail Enters into Commercial Alliance for Aplenzin(TM)
12/01/2008 8:03 AM
Biovail Announces Filing of ANDA for Quetiapine XR Tablets
11/24/2008 9:03 AM
Biovail Announces U.S. Availability of Xenazine(R) Tablets
11/11/2008 12:01 PM
Biovail to Participate at Upcoming Conferences
11/06/2008 7:33 AM
Biovail Reports Third-Quarter 2008 Financial Results
11/06/2008 7:31 AM
Biovail Declares Quarterly Dividend
11/06/2008 7:03 AM
Biovail Appoints Dr. H. Christian Fibiger Senior Vice-President, Chief Scientific Officer
10/28/2008 4:16 PM
Biovail Announces Third-Quarter 2008 Earnings Release, Conference-Call Details
10/09/2008 8:20 AM
Biovail Comments on Filing of Lawsuit
10/07/2008 3:16 PM
Biovail to Present at Natixis Bleichroeder Hidden Gems Conference
09/18/2008 3:46 PM
Biovail to Participate at Upcoming Investor Conferences
09/17/2008 7:31 AM
Biovail Acquires Prestwick Pharmaceuticals
09/03/2008 4:01 PM
Biovail Announces Filing of ANDA for Fenofibrate Tablets
08/25/2008 1:00 PM
Biovail Receives Canadian Approval for Ralivia(TM) for the Treatment of Moderately Severe Pain
08/21/2008 8:01 AM
Biovail Appoints Peggy Mulligan Chief Financial Officer
08/20/2008 8:01 AM
Biovail Appoints Dr. Neil M. Sussman Vice-President, Neurologic & Psychiatric Development
08/13/2008 7:31 AM
Biovail Reports Second-Quarter 2008 Financial Results
08/13/2008 7:30 AM
Biovail Declares Quarterly Dividend
08/08/2008 12:55 PM
Biovail Shareholders Confirm Election of Company Board Nominees
08/06/2008 9:00 PM
Biovail Waives Proxy Voting Cut-Off
07/30/2008 8:03 AM
Biovail Announces Second-Quarter 2008 Earnings Release, Conference-Call Details
07/29/2008 8:03 AM
Biovail Reminds Shareholders to Vote FOR the Biovail Nominees Using BLUE Proxy
07/21/2008 9:16 AM
Biovail to Reconvene Annual Meeting on August 8, 2008
07/16/2008 12:56 PM
Biovail to Reconvene Annual Meeting of Shareholders as Soon as Reasonably Possible
06/25/2008 2:41 PM
Biovail Comments on Eugene Melnyk's Continued Distortion of the Facts
06/20/2008 3:00 PM
Biovail Provides Shareholders With Additional Analyst Commentary
06/19/2008 3:17 PM
Biovail Reminds Shareholders of Deadline for Decision on the Future of Their Company
06/19/2008 8:11 AM
Biovail Comments on Glass Lewis Report
06/18/2008 3:44 PM
Biovail Announces That a Second Proxy Advisory Firm Recommends Shareholders Vote for Biovail's Director Nominees
06/17/2008 9:40 AM
Biovail Dismisses Inappropriate and Unnecessary Debate
06/16/2008 5:28 PM
Biovail CEO Bill Wells BNN Interview Available on Company Website
06/16/2008 1:36 PM
Biovail Recommends Shareholders Vote to Move Forward from the Melnyk Lost Years
06/16/2008 7:02 AM
REPEAT/Biovail Announces That RiskMetrics Group Recommends Shareholders Vote ''For'' Biovail's Director Nominees
06/14/2008 8:41 AM
Biovail Announces That RiskMetrics Group Recommends Shareholders Vote ''For'' Biovail's Director Nominees
06/13/2008 1:28 PM
Biovail Provides Update on Share Repurchase Program
06/10/2008 12:42 PM
Biovail to Present at 2008 Goldman Sachs Global Healthcare Conference
06/09/2008 7:31 PM
Biovail Shareholders Should Disregard the Latest Misinformation from Eugene Melnyk
06/05/2008 8:08 PM
Biovail Responds to Dissident Circular
06/03/2008 7:02 AM
Biovail Notes Filing of Dissident Circular
05/27/2008 9:04 AM
Biovail Launches Normal Course Issuer Bid
05/16/2008 2:06 PM
Biovail Subsidiary Reaches Settlement with United States Department of Justice
05/16/2008 8:02 AM
Biovail Announces Mailing and Filing of Management Proxy Circular
05/13/2008 12:06 PM
Biovail to Present at 2008 Citi Investment Research Global Healthcare Conference
05/08/2008 7:33 AM
Biovail Reports First-Quarter 2008 Financial Results
05/08/2008 7:33 AM
Biovail Declares Quarterly Dividend
05/08/2008 7:32 AM
Biovail Announces New Strategic Focus
05/08/2008 7:32 AM
Biovail Announces Normal Course Issuer Bid
04/28/2008 1:07 PM
Biovail Announces First-Quarter 2008 Earnings Release, Conference-Call Details
04/23/2008 5:52 PM
Biovail Receives FDA Approval for Aplenzin (BVF-033)
04/23/2008 8:01 AM
Biovail Settles Canadian Securities Class-Action Litigation
04/21/2008 8:24 PM
Biovail Announces Resignation of Director Bill Bristow
04/21/2008 9:01 AM
Biovail Announces Changes to Board Committees
04/21/2008 8:32 AM
Biovail Strengthens Leadership Team
04/10/2008 10:11 AM
Biovail Announces Withdrawal of Legal Action by Eugene Melnyk
03/28/2008 5:26 PM
Biovail Announces Resignation of Director Jamie Sokalsky
03/24/2008 11:06 AM
Biovail Reaches Settlement With SEC, Provides Update On OSC Investigation
03/13/2008 7:32 AM
Biovail Declares Quarterly Dividend
03/13/2008 7:31 AM
Biovail Reports Fourth Quarter and Year-End 2007 Financial Results, Provides Strategy Update
03/07/2008 12:01 PM
Biovail Announces Fourth-Quarter, Full-Year 2007 Earnings Release, Conference-Call Details
02/27/2008 8:04 AM
Biovail Announces Change in Board of Directors
02/15/2008 1:01 PM
Biovail Receives Canadian Approval for Wellbutrin(R) XL for the Prevention of Seasonal Major Depressive Illness
02/04/2008 5:16 PM
Biovail to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
02/01/2008 8:02 AM
Biovail Receives Letter Related to 2003 Cardizem(R) LA Launch Activities from U.S. Attorney's Office
01/24/2008 8:05 AM
Biovail Announces Canadian Commercial Availability of 1,000mg Dosage of Glumetza(TM)
01/02/2008 8:01 AM
Biovail Announces Supply Agreement for Commercialization of Extended-Release Tramadol
12/11/2007 8:21 AM
Biovail Announces Proposed Settlement of U.S. Securities Class Action
12/10/2007 8:01 AM
Biovail Appoints Lloyd Segal to Company's Board of Directors
12/06/2007 4:46 PM
Biovail to Participate at the RBC Capital Markets 2007 Healthcare Conference
12/04/2007 7:06 AM
Biovail Announces Settlement Agreement Related to Cardizem(R) LA
11/22/2007 12:01 PM
Biovail to Present at the Lazard Capital Markets 4th Annual Healthcare Conference
11/20/2007 8:02 AM
Biovail Confirms FDA Class 2 Status For BVF-033 Submission
11/09/2007 12:31 PM
Biovail to Present at the 2007 Annual Credit Suisse Health Care Conference
11/08/2007 7:33 AM
Biovail Reports Third-Quarter 2007 Financial Results
11/08/2007 7:32 AM
Biovail Declares Quarterly Dividend
11/07/2007 9:15 AM
Biovail Enters into Development Agreement
11/01/2007 5:05 PM
Biovail"s Steinbach Manufacturing Facility Received Prestigious Manitoba Business Award
11/01/2007 8:02 AM
Biovail Launches Ralivia(TM) to Canadian Physicians
10/25/2007 8:01 AM
Biovail Announces Third-Quarter 2007 Earnings Release, Conference-Call Details
10/24/2007 8:02 AM
Biovail Submits Complete Response to FDA for BVF-033
10/02/2007 3:54 PM
Biovail to Present at Natixis Bleichroeder's Hidden Gems Conference
09/19/2007 3:31 PM
Biovail to Present at CIBC World Markets Conference
09/14/2007 3:05 PM
Biovail to Present at the UBS 2007 Global Life Sciences Conference
09/10/2007 5:23 PM
Biovail Says Settlement With Maris, BAS Expected to Be Helpful in Suit Against Hedge Funds and Others
09/04/2007 8:06 AM
Biovail Receives Canadian Approval for Ralivia(TM)
08/08/2007 7:33 AM
Biovail Declares Quarterly Dividend
08/08/2007 7:32 AM
Biovail Reports Second-Quarter 2007 Financial Results
08/08/2007 7:31 AM
Biovail Enters Into License and Development Agreement
07/24/2007 12:01 PM
Biovail Announces Second-Quarter 2007 Earnings Release, Conference-Call Details
07/23/2007 12:55 PM
Biovail Responds to Investor Enquiries
07/20/2007 8:02 AM
Biovail Provides Update on BVF-033
06/28/2007 4:04 PM
Biovail Board of Directors Appoints Dr. Douglas Squires Interim Chairman
06/22/2007 5:32 PM
Biovail Acknowledges Chairman's Filing of Report with the Ontario Securities Commission
06/07/2007 11:01 AM
Biovail to Present at the Goldman Sachs Twenty-Eighth Annual Global Healthcare Conference
06/01/2007 8:02 AM
Biovail Files Amended 2006 Annual Report on Form 20-F with United States Securities and Exchange Commission
05/18/2007 5:36 PM
Biovail Chairman Eugene Melnyk Reaches Settlement with Ontario Securities Commission
05/18/2007 11:31 AM
Biovail to Present at Citigroup 2007 Healthcare Conference
05/16/2007 8:18 AM
Biovail Chairman Eugene Melnyk Announces Retirement
05/15/2007 8:49 PM
Biovail Acknowledges Wells Notices Received by Company Executives
05/14/2007 8:03 AM
Biovail Acknowledges Receipt of Wells Notice
05/10/2007 7:31 AM
Biovail Declares Quarterly Dividend
05/10/2007 12:00 AM
Biovail Reports First-Quarter 2007 Financial Results, Plans to File Amended 2006 Form 20-F
04/26/2007 12:01 PM
Biovail to Present at the Morgan Stanley Global Healthcare Unplugged Conference
04/25/2007 11:01 AM
Biovail Announces First-Quarter 2007 Earnings Release, Conference-Call Details
04/03/2007 12:00 PM
Biovail to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
03/23/2007 2:01 PM
Biovail to Present at the Scotia Capital Spring Growth Conference
03/15/2007 7:31 AM
Biovail Declares Quarterly Dividend
03/15/2007 7:31 AM
Biovail Reports Record Fourth Quarter, Year-End 2006 Financial Results
03/05/2007 8:03 AM
Biovail Announces Comprehensive Settlement Related to Wellbutrin XL(R)
02/28/2007 7:01 AM
Biovail Calls for Redemption All Outstanding Senior Subordinated Notes Due 2010
02/27/2007 7:01 AM
Biovail Announces Fourth-Quarter, Full-Year 2006 Earnings Release, Conference-Call Details
02/12/2007 12:00 AM
Biovail and Depomed Sign License Agreement For Acuform (TM) Drug-Delivery Technology
02/02/2007 12:31 PM
Biovail to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
01/19/2007 11:32 AM
Biovail to Present at the JPMorgan Annual High Yield Conference 2007
01/16/2007 9:04 AM
Wellbutrin XR(R) Receives First European Approval
12/20/2006 10:46 AM
Biovail Enters into Exclusive Promotional Agreement for Zovirax(R)
12/11/2006 3:00 PM
Biovail to Participate at the 2006 RBC Capital Markets Healthcare Conference
12/06/2006 8:32 AM
Biovail Provides Financial Update, 2007 Guidance
12/06/2006 8:31 AM
Biovail Provides Strategy Update
12/06/2006 7:01 AM
Biovail Announces Senior Management Change
11/13/2006 11:02 AM
Biovail to Present at the CSFB 2006 Healthcare Conference
11/09/2006 7:32 AM
Biovail Updates 2006 Guidance
11/09/2006 7:32 AM
Biovail Declares Quarterly Dividend
11/09/2006 7:32 AM
Biovail Reports Third-Quarter 2006 Financial Results
10/23/2006 10:32 AM
Biovail Announces Third-Quarter 2006 Earnings Release, Conference-Call Details
10/02/2006 11:01 AM
Biovail to Present at Upcoming Conferences
09/21/2006 1:01 PM
Biovail to Present at the UBS 2006 Global Life Sciences Conference
08/24/2006 8:01 AM
Biovail Commences Legal Action to Enforce Criteria Set Forth in Its Citizen Petition
08/10/2006 7:31 AM
Biovail Declares Quarterly Dividend
08/10/2006 7:31 AM
Biovail Reports Second-Quarter 2006 Financial Results; Company Records Total Revenues of $253 Million; U.S. GAAP EPS of $0.50; Cash Balances in Excess of $570 Million; Cash Flows from Operations of $111 Million
08/10/2006 7:31 AM
Biovail Updates 2006 Guidance
08/04/2006 8:01 AM
Biovail Announces Second-Quarter 2006 Earnings Release, Conference-Call Details
08/02/2006 10:56 AM
Biovail Comments on Wellbutrin XL(R) Court Ruling
07/31/2006 11:26 AM
Biovail Acknowledges Chairman Receives Notice of Hearing from the OSC
07/24/2006 8:01 AM
Biovail and Athpharma Terminate Joint Development Agreement
07/12/2006 8:01 AM
Biovail Appoints General Counsel
06/27/2006 11:12 AM
Biovail Announces Results of 2005 Annual and Special Meeting of Shareholders; Chairman Eugene Melnyk Provides Governance Update; Chief Executive Officer Douglas Squires Provides 2005 Operational Recap
06/16/2006 8:01 AM
Biovail Renews Revolving Term Credit Facility
06/12/2006 10:01 AM
Biovail to Present at the Goldman Sachs Twenty-Seventh Annual Global Healthcare Conference
05/25/2006 5:31 PM
Biovail Corporation Commences Offer to Purchase $56.6 Million of Its Subordinated Notes
05/19/2006 8:01 AM
Biovail to Promote Novartis' Lescol(R) Franchise in Canada; Lescol(R) Provides Treatment Option for Patients Who Need a Statin to Reduce Cardiovascular Risk
05/11/2006 7:31 AM
Biovail Declares Quarterly Dividend
05/11/2006 7:31 AM
Biovail Reports First-Quarter 2006 Financial Results; Company Records Total Revenues of $220.5 Million; Operating Margins of 35.1%; EPS From Continuing Operations of $0.43; Cash Flow From Operations of $94.7 Million
05/09/2006 10:31 AM
Biovail Appoints Dr. Peter Silverstone Senior Vice-President
05/04/2006 1:00 PM
Biovail Announces First-Quarter 2006 Earnings Release, Conference-Call Details
05/02/2006 1:01 PM
Biovail to Present at the Morgan Stanley Global Healthcare Unplugged Conference
05/02/2006 8:02 AM
Biovail to Promote AstraZeneca's Zoladex(R) 3.6mg (Goserelin Acetate Implant) for Endometriosis in the United States and Puerto Rico
04/28/2006 4:46 PM
Biovail to Present at the Deutsche Bank Annual Health Care Conference
04/27/2006 7:02 AM
Biovail Names Gilbert Godin Senior Vice-President
04/21/2006 3:01 PM
Biovail to Present at the Scotia Capital Pharmaceutical & Biotechnology Conference
04/20/2006 4:06 PM
Biovail to Present at the UBS Global Specialty Pharmaceuticals Conference
04/12/2006 8:01 AM
Biovail Launches Wellbutrin XL to Canadian Physicians
03/31/2006 10:48 AM
Biovail to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
03/23/2006 7:31 AM
Biovail Reports Fourth Quarter, Year-End 2005 Financial Results
03/23/2006 7:31 AM
Biovail Provides 2006 Guidance
03/23/2006 7:31 AM
Biovail Declares Quarterly Dividend
03/20/2006 2:15 PM
Biovail Announces Fourth-Quarter, Full-Year 2005 Earnings Release, Conference-Call Details
03/07/2006 8:31 AM
Biovail Announces Changes to Organizational Structure; Company Realigned into Three Business Units
02/22/2006 4:17 PM
Biovail Files Lawsuit Alleging Stock Market Manipulation Scheme
02/21/2006 12:00 AM
Once Daily ULTRAM(R) ER Extended-Release Tablets Now Available in the United States
02/15/2006 11:32 AM
Biovail to Present at the CIBC World Markets 2006 Whistler Institutional Investor Conference
02/03/2006 10:30 AM
Biovail to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
02/02/2006 4:29 PM
Biovail to Present at the JPMorgan Annual High Yield Conference 2006
01/17/2006 8:32 AM
Biovail Receives Approval for Wellbutrin(R) XL to Treat Depression in Canada
01/11/2006 9:02 AM
Biovail to Present at 24th Annual JPMorgan Healthcare Conference
12/21/2005 1:56 PM
Biovail Submits Citizen Petition to FDA
12/21/2005 8:31 AM
Biovail Receives FDA Approval for Citalopram ODT
12/13/2005 4:09 PM
Depomed, Biovail Revise Partnership Agreement for Development, Commercialization of Glumetza(tm); Depomed to Have Rights for United States; Biovail to Have Rights for Canada
12/02/2005 2:01 PM
Biovail, Ortho-McNeil Partnership Receives Hart-Scott-Rodino Regulatory Clearance
11/29/2005 8:32 AM
Biovail Launches Glumetza to Canadian Physicians
11/16/2005 10:01 AM
Biovail to Present at the CSFB 2005 Health Care Conference
11/15/2005 7:01 AM
Biovail to Spin off Legacy Assets
11/11/2005 7:31 AM
Biovail Reports Third-Quarter 2005 Financial Results
11/09/2005 9:05 AM
Biovail Announces Third-Quarter 2005 Earnings Release, Conference-Call Details
11/03/2005 4:16 PM
Biovail Enters Into Commercial Alliance for Tramadol Products
10/21/2005 5:45 PM
Biovail Exclusivity for Tramadol ER Confirmed by FDA
10/20/2005 8:31 AM
Biovail to Present Case Study on Corporate Governance
10/19/2005 3:01 PM
Biovail Receives Important Corporate-Governance Recognition; Executive Chairman Eugene Melnyk Pleased with Progress; Stresses More to be Done
10/07/2005 5:56 PM
Biovail Updates Status of Previously Disclosed OSC Investigation
09/23/2005 12:11 PM
Biovail to Present at the UBS 2005 Global Life Sciences Conference
09/09/2005 7:30 AM
Biovail's Tramadol ER Receives FDA Approval
08/04/2005 7:32 AM
Biovail Reports Second-Quarter 2005 Financial Results
07/21/2005 8:47 AM
Biovail Announces Second-Quarter 2005 Earnings Release, Conference-Call Details
06/28/2005 10:29 AM
Biovail Announces Results of 2004 Annual and Special Meeting of Shareholders
06/20/2005 4:13 PM
Biovail to Host Investor Event in Toronto
06/14/2005 11:46 AM
Biovail to Present at the Goldman Sachs Twenty-Sixth Annual Global Healthcare Conference
06/13/2005 10:48 AM
Biovail to Present at the Merrill Lynch Canada 12th Annual Growth Stock Conference
06/03/2005 2:39 PM
Biovail, Depomed Receive FDA Approval for Extended-Release Glumetza for Type II Diabetes; Enhanced Formulation to Offer Physicians Potential Advantages
06/01/2005 8:33 AM
Biovail, Depomed Announce Regulatory Approval of Glumetza to Treat Type II Diabetes in Canada
05/27/2005 8:31 AM
Biovail Receives Tentative Approval From FDA for Zolpidem ODT for Sleep Disorders
05/26/2005 8:32 AM
Biovail Renews Revolving Term Credit Facility
05/20/2005 1:01 PM
Biovail to Present at the UBS 2005 Global Pharmaceuticals Conference
05/20/2005 8:31 AM
Biovail Announces Further Corporate-Governance Enhancements
05/17/2005 11:54 AM
Biovail to Present at the Banc of America Securities Health Care Conference 2005
05/16/2005 10:02 AM
Biovail to Present at the Bear Stearns 14th Annual Global Credit Conference
05/10/2005 9:23 AM
Biovail to Present at the UBS Leveraged Finance Conference
05/06/2005 8:45 AM
Biovail Receives Approval Letter From FDA For Tramadol ODT; Oral Disintegrating Tablet Version to Provide Treatment Option for Those Who Suffer from Moderate to Moderately Severe Pain
05/05/2005 1:23 PM
Biovail to Present at the Morgan Stanley Third Annual Global Healthcare Unplugged Conference
05/05/2005 11:01 AM
Biovail Updates 2005 Guidance; Company Provides Amortization Guidance; Strategic Transaction With Kos Results in Increased EPS Guidance; Diluted EPS Guidance Range Now $1.70 - $1.75 vs. $1.50 - $1.60 Excluding Certain Charges
05/05/2005 7:32 AM
Biovail Reports First-Quarter 2005 Financial Results
05/05/2005 7:32 AM
Biovail Reports Significant Improvements in Corporate Governance
05/03/2005 7:06 AM
Biovail Realigns U.S. Commercial Organization
04/19/2005 8:31 AM
Biovail Announces First Quarter 2005 Earnings Release, Conference Call Details
04/04/2005 8:34 AM
Court Rules in Favor of Biovail in Tiazac Class Actions
04/01/2005 1:16 PM
Biovail to Present at the CIBC World Markets Annual Biotechnology & Specialty Pharmaceuticals Conference
03/30/2005 2:09 PM
Biovail to Present at the Smith Barney Citigroup 2005 Healthcare Conference
03/30/2005 8:33 AM
Biovail Updates Status of NDA for Tramadol ER
03/10/2005 7:34 AM
Biovail Provides 2005 Guidance & Strategy Update
03/10/2005 7:32 AM
Biovail Reports Fourth Quarter, Year-End 2004 Financial Results
03/04/2005 8:30 AM
Biovail Updates Status of SEC Inquiry
03/01/2005 8:33 AM
Biovail, Depomed Receive Approvable Letter from FDA for Extended-Release Glumetza for Type II Diabetes
02/28/2005 10:26 AM
Biovail Announces Fourth Quarter 2004, Year-End Earnings Release, Conference-Call Details
02/22/2005 12:01 PM
Biovail Announces $27.6-Million Expansion to Steinbach, Manitoba Manufacturing Facility
02/03/2005 8:31 AM
Biovail Announces Further Corporate-Governance Enhancement Measures
01/25/2005 8:31 AM
Biovail Launches Tiazac XC To Canadian Physicians
01/12/2005 12:05 PM
Biovail Receives Approvable Letter for Tramadol ODT
01/10/2005 8:33 AM
Biovail to Present at JPMorgan Healthcare Conference; Company Provides Update on Corporate Governance
12/22/2004 9:05 AM
Biovail Commences Legal Action Related to ANDAs Filed for Wellbutrin XL
12/06/2004 8:31 AM
Biovail Names Dr. Michael Yeomans Senior Vice-President, Global Business Development
11/19/2004 6:11 PM
Biovail Aware of Second Paragraph IV Certification for Wellbutrin XL
11/17/2004 8:32 AM
Biovail Confirms Receipt of Notification of ANDA Submission for Wellbutrin XL
11/09/2004 9:20 AM
Webcast Alert: Biovail Corporation Presentation at Informed Investors International Pharmaceuticals Virtual Forum to be Webcast on Tuesday, November 9, 2004, 3:30 pm ET
11/04/2004 7:02 AM
Biovail Reports Third Quarter 2004 Financial Results
11/01/2004 8:32 AM
Biovail's Ralivia ER Receives Approvable Letter From FDA
10/25/2004 8:31 AM
Biovail's Supplemental NDS For TIAZAC XC Accepted For Review by Therapeutic Products Directorate in Canada
10/13/2004 8:31 AM
Biovail Announces Third Quarter 2004 Earnings Release, Conference-Call Details
10/07/2004 4:16 PM
Biovail Appoints Dr. Douglas J.P. Squires Chief Executive Officer
10/01/2004 8:31 AM
Biovail and Teva Announce Resolution of Arbitration Proceedings; Expansion of Relationship
09/07/2004 8:32 AM
Biovail Updates 2004 Financial Guidance
09/02/2004 8:31 AM
Moses Trial Shows TEVETEN -- Eprosartan -- Reduces Risk Of Second Stroke in Hypertensive Stroke Patients; Results Presented at European Society of Cardiology Congress in Munich
08/27/2004 8:31 AM
Biovail, Schering-Plough Terminate CEDAX Agreements; Shionogi & Co. Ltd. to Market CEDAX in United States
08/17/2004 9:48 AM
Biovail Announces Regulatory Approval of Tiazac XC to Treat Hypertension in Canada
08/13/2004 5:54 PM
Biovail Announces Block Trades
08/10/2004 9:04 AM
Biovail and Depomed Announce Glumetza NDS Acceptance
08/04/2004 8:55 AM
Biovail Provides Guidance Update
08/04/2004 7:53 AM
Biovail Announces Changes to Executive Management Team
08/04/2004 7:51 AM
Biovail Reports Second Quarter 2004 Financial Results
07/19/2004 8:16 AM
Biovail Names John Sebben Vice-President Global Manufacturing
07/14/2004 10:08 AM
Biovail Announces Second Quarter 2004 Earnings Release, Conference-Call Details
06/25/2004 11:30 AM
Biovail Announces Results of 2003 Annual and Special Meeting of Shareholders
06/24/2004 8:31 AM
Biovail, Depomed Announce Glumetza NDA Accepted by FDA
06/14/2004 8:12 AM
Biovail Files NDA For Novel Dosage Form of Anti-Depressant
06/11/2004 8:45 AM
Biovail Amends 2004 Stock Option Plan Proposal
04/29/2004 7:32 AM
Biovail Reports 2004 First Quarter Financial Results
04/28/2004 8:02 AM
Biovail and Depomed Submit NDA for Glumetza; Submission Includes 500mg and 1000mg dosages; Biovail/Depomed Expand Royalty Agreement to Include 1000mg dose
04/22/2004 12:03 PM
Biovail Announces First Quarter 2004 Earnings Release Conference Call Details
04/05/2004 8:06 AM
FDA Approves Biovail's Cardizem LA for the Treatment of Angina; New Specialty Sales Force to Promote Additional Angina Indication
03/23/2004 3:29 PM
Biovail Renews Revolving Term Credit Facility
03/11/2004 12:45 PM
Biovail Submits NDA for Ralivia FlashDose
03/09/2004 3:59 PM
Biovail Comments on Rating Agency Outlooks
03/03/2004 8:18 AM
Biovail Confirms 2003 Fourth Quarter and Year End Earnings Release Conference Call Details
03/03/2004 7:31 AM
Biovail Commences Arbitration
03/03/2004 7:29 AM
Biovail Provides Updated 2004 Guidance
03/03/2004 6:48 AM
Biovail Reports 2003 Fourth Quarter and Full Year Financial Results
02/26/2004 6:40 PM
Biovail NDA For Ralivia ER -- Tramadol Extended Release Tablets -- Accepted for Review
02/26/2004 12:31 PM
Biovail Acquires Rights to Novel Formulations of Eprosartan and Carvedilol
02/10/2004 6:02 PM
CORRECTING and REPLACING Biovail Announces 2003 Fourth Quarter and Year End Earnings Release Conference Call Details
02/10/2004 8:03 AM
Biovail Announces 2003 Fourth Quarter and Year End Earnings Release Conference Call Details
01/08/2004 12:23 PM
Biovail to Present at 22nd JP Morgan Healthcare Conference
12/24/2003 8:03 AM
Biovail and Reliant Terminate Co-Promote Arrangement; Biovail Credit Facility Extended
12/22/2003 8:06 AM
Biovail Announces Conclusion of FTC Patent Inquiry
12/10/2003 5:44 PM
Biovail Announces Block Trade
12/09/2003 7:33 AM
Biovail Comments on Wellbutrin XL Global Marketing Status
11/24/2003 5:01 PM
Biovail Receives Regulatory Approval to Make Normal Course Issuer Bid
11/21/2003 12:27 PM
Biovail Announces Intention to Make a Normal Course Issuer Bid
11/20/2003 6:12 PM
Biovail Confirms Informal Inquiry by SEC
11/13/2003 8:58 AM
Biovail Comments on Class Action Complaint
11/07/2003 2:36 PM
Biovail to Present at Credit Suisse First Boston Health Care Conference in Phoenix
11/07/2003 2:08 PM
Biovail to Present at CIBC World Markets' Fourteenth Annual Healthcare Conference
10/30/2003 11:29 AM
Biovail Reports Third Quarter 2003 Financial Results - Correction
10/30/2003 8:46 AM
Biovail Reports Third Quarter 2003 Financial Results
10/30/2003 8:46 AM
Biovail Provides 2004 Guidance
10/30/2003 8:33 AM
Biovail Corporation Makes Announcement
10/23/2003 4:55 PM
Biovail announces third quarter 2003 earnings release conference call details
10/16/2003 7:54 AM
Biovail Announces Third Quarter 2003 Earnings Release Date
10/08/2003 1:56 PM
Biovail Confirms Wellbutrin XL Shipment Recovery
10/03/2003 10:14 AM
Biovail Provides Guidance on 2003 Third Quarter Results
08/29/2003 7:32 AM
FDA Approves Wellbutrin XL -- New, Once-Daily Antidepressant with Low Risk of Sexual Side Effects and Weight Gain
08/22/2003 6:10 PM
Biovail Receives Administrative Inquiry
07/29/2003 7:34 AM
Biovail Reports Record Second Quarter 2003 Financial Results
07/23/2003 9:10 AM
Biovail Confirms FDA Class I Status for Wellbutrin XL Submission
07/22/2003 5:36 PM
Biovail Announces Second Quarter 2003 Earnings Release Conference Call Details
07/09/2003 4:32 PM
Biovail Confirms Submission of Response to Wellbutrin XL Approvable Letter
07/02/2003 11:24 AM
Biovail Submits Cardizem LA NDA for Angina
06/26/2003 7:33 AM
Biovail Announces Receipt of an Approvable Letter for Wellbutrin XL
06/05/2003 8:00 AM
Biovail Appoints Praveen Tyle Group Vice President, Pharmaceutical Sciences and Manufacturing Operations
06/02/2003 10:07 AM
Biovail Corporation to Present at UBS Warburg Global Specialty Pharmaceutical Conference
06/02/2003 8:00 AM
Biovail Acquires Ativan and Isordil from Wyeth
05/16/2003 3:31 PM
Study Shows Nighttime Dosing of Biovail's Cardizem LA May Be More Effective Than Norvasc in Controlling Morning Blood Pressure and Other Risks in Hypertensive African-Americans
05/16/2003 3:31 PM
Study Shows Nighttime Dosing of Biovail's Cardizem LA Lowers Blood Pressure and Other Risks More Than Nighttime Dosing of Altace
05/14/2003 7:46 AM
Biovail Presents Three Poster Presentations at the American Society of Hypertension
05/07/2003 8:13 AM
Biovail's Cardizem LA Obtains Favorable Formulary Coverage; Access to over 74 Million Managed Care Lives
05/06/2003 9:15 AM
Biovail Appoints Kristine Peterson Senior Vice President, Commercial Operations
04/29/2003 7:34 AM
Biovail Reports Positive CardizemLA Launch Results
04/29/2003 7:34 AM
Biovail Reports Record First Quarter 2003 Financial Results
04/28/2003 5:56 PM
Biovail Acquires Four Cardiovascular Pipeline Products from Athpharma Limited
04/25/2003 8:08 AM
Biovail Appoints Gregory Szpunar Senior Vice President, Research & Development and Chief Scientific Officer
04/09/2003 12:00 AM
Biovail Acquires Rights to Controlled Release Acyclovir -Genvir- from Flamel Technologies
04/02/2003 8:14 AM
Biovail Launches Cardizem LA to
Physicians; Schedules Q1 Earnings Release for April 29, 2003
03/30/2003 1:01 PM
Biovail: Study Suggests Bedtime Dose of Cardizem LA Protects Angina Patients from Morning Risks
03/28/2003 4:22 PM
Biovail to Present at American College of Cardiology in Chicago on March 29 & 30, 2003
03/05/2003 8:12 AM
Biovail Reports Clinical Trial Results
03/04/2003 7:37 AM
Biovail Reports Record Fourth Quarter and Full Year 2002 Financial Results
02/27/2003 12:00 AM
Biovail Announces Fourth Quarter and Year End 2002 Earnings Release Conference Call Details
02/20/2003 11:52 AM
Biovail Announces FDA Approval of Teveten HCT for Hypertension - Promotional Activities for This Combination ARB/Diuretic Product Will Begin March 10, 2003 -
02/07/2003 8:16 AM
Biovail Provides 2003 Guidance
02/07/2003 7:51 AM
FDA Approves Biovail's Cardizem LA for Hypertension
02/03/2003 8:06 AM
Biovail and DepoMed Report Positive Phase III Clinical Results for Metformin GR Extended Release Formulation
01/03/2003 8:20 AM
Biovail Announces FDA Approval for Zovirax Cream
12/27/2002 8:05 AM
Biovail Acquires Canadian Rights to Wellbutrin SR & Zyban From GlaxoSmithKline
12/27/2002 8:05 AM
Biovail Announces Extended Marketing Agreement for Zovirax Ointment and Zovirax Cream; Biovail Extends Promotion Agreement for Zovirax products by Ten Years
12/11/2002 7:35 AM
Biovail Acquires Pharma PASS Companies for $190 Million
11/14/2002 7:08 AM
Biovail Expands Co-Promotion Arrangement With Reliant Pharmaceuticals for Cardizem XL
11/01/2002 9:58 AM
Biovail Receives FDA Tentative Approval for Flash Dose Zolpidem
10/29/2002 12:00 AM
Biovail Enters Into a Co-Promotion Arrangement With Reliant Pharmaceuticals
10/29/2002 12:00 AM
Ramipril Comprehensive: Biovail Reports Positive Phase IV Clinical Trial Results for Graded Release Diltiazem -- G-99 -- Versus Ramipril
10/29/2002 12:00 AM
Angina Comprehensive: Biovail Reports Positive Phase III Clinical Trial Results for Graded Release Diltiazem -- G-99 -- In Chronic Stable Angina Pectoris
10/29/2002 12:00 AM
Biovail Reports Record Third Quarter 2002 Results
10/28/2002 8:03 AM
Biovail Presents Tramadol Results at American College of Rheumatology
10/18/2002 12:43 PM
Biovail Third Quarter 2002 Earnings Release Conference Call Details
09/16/2002 8:22 AM
Biovail Warrants Expire September 30, 2002
08/27/2002 10:11 AM
Biovail Announces FDA Submission for Once-daily Bupropion HCl Formulation by GlaxoSmithKline
08/19/2002 9:42 AM
Biovail's Generic Adalat CC 90mg Receives Final Approval
07/25/2002 7:19 AM
Biovail Reports Record Second Quarter 2002 Results
07/17/2002 4:34 PM
Biovail Announces Second Quarter 2002 Earnings Release Conference Call Details
07/11/2002 10:39 AM
Andrx and Biovail Execute Settlement Agreement
07/09/2002 2:33 PM
Biovail Responds to Media Enquiries
06/27/2002 10:29 AM
Biovail Reaches FTC Settlement Regarding Adalat Agreement
06/17/2002 9:18 AM
Biovail Receives Approvable Letter for Cardizem XL
05/31/2002 2:38 PM
Biovail Corporation Announces Increase in Its Normal Course Issuer Bid
05/29/2002 8:08 AM
Biovail Acquires Metformin GR Product Rights From DepoMed; Accelerates Anticipated Commercialization Timelines; Biovail Acquires a 15% Interest in DepoMed
05/17/2002 12:53 PM
Biovail Increases 2002 Total Revenue Guidance
05/17/2002 10:07 AM
Biovail Increases 2002 Revenue Guidance
05/17/2002 7:34 AM
Biovail Reports New Graded-Release Diltiazem Helps Control Blood Pressure Surges
05/17/2002 12:05 AM
Blood Pressure Medication is Not Administered to Best Protect Against Heart Attack, Stroke
05/16/2002 12:18 PM
Biovail Comments On Media Reports
05/12/2002 2:47 PM
Biovail Acquires Vasotec-R / Vaseretic-R From Merck & Co., Inc.
04/25/2002 3:52 PM
Biovail Reiterates Earnings Guidance
04/25/2002 7:32 AM
Biovail Reports Record First Quarter 2002 Financial Results
04/23/2002 12:00 AM
Biovail Confirms FTC Settlement
04/22/2002 11:42 AM
Biovail Announces First Quarter 2002 Earnings Release Conference Call Details
04/15/2002 12:00 AM
Biovail to Commercialize Six Ethypharm Pipeline Products in North America
03/26/2002 9:06 AM
Biovail Prices US$400 Million 7.875% Senior Subordinated Notes Due 2010
03/20/2002 7:34 AM
Biovail Announces Offering of US$275 Million Senior Subordinated Notes Due 2010
03/18/2002 7:32 AM
Biovail Acquires Teveten and Teveten HCT U.S. Marketing Rights From Solvay Pharmaceuticals Marketing and Licensing AG
02/21/2002 8:02 AM
Biovail and Andrx Agree to Litigation Settlement
02/21/2002 7:34 AM
Biovail Reports Record Fourth Quarter and Full Year 2001 Results
02/19/2002 5:28 PM
Biovail Announces Fourth Quarter 2001 Earnings Release Conference Call Details
02/08/2002 4:32 PM
Biovail Board Approves Stock Repurchase Program
01/24/2002 2:50 PM
Biovail Releases Earnings Guidance; Biovail Expects to Exceed Consensus Earnings Estimates for 2001; Reconfirms Comfort With EPS Growth in Excess of 30% for 2002 and 2003
01/14/2002 8:32 AM
Biovail Reports Second Positive Phase III Clinical Result for Tramadol Extended Release Formulation
01/10/2002 8:48 AM
Biovail Files NDA for Zolpidem FlashDose Product
12/10/2001 9:32 AM
Biovail Receives Hart-Scott-Rodino Approval; Biovail Begins Co-Promotion of Wellbutrin SR Immediately; Initiates 500 Person Sales Force Expansion Program
11/28/2001 8:02 AM
Biovail Completes Convertible Securities Redemption
11/15/2001 5:03 PM
Biovail Over-Allottment Option Exercised
11/15/2001 5:02 PM
Biovail Over-Allottment Option Exercised by Underwriters
11/14/2001 8:39 AM
Biovail Prices Share Offering
11/05/2001 6:07 PM
Biovail Announces Public Offerings
10/29/2001 7:10 AM
Biovail and GlaxoSmithKline Sign Licensing Agreements for Once Daily Formulation of Wellbutrin and Distribution Rights for Zovirax Ointment & Cream
10/29/2001 7:03 AM
Biovail Reports Record Third Quarter 2001 Results
10/27/2001 7:45 PM
Biovail Calls for Redemption of Its Outstanding 6.75% Convertible Securities and Files a Preliminary Shelf Prospectus With Securities Commissions
10/23/2001 3:10 PM
Biovail Announces Third Quarter 2001 Earnings Release Date
10/02/2001 7:49 AM
Biovail Files NDA for Fluoxetine Flash Dose Brand
09/21/2001 9:10 AM
Biovail Comments On Decision of District Court Southern District of Florida; Biovail Appealing Court's Decision; Biovail Reconfirms Comfort With Consensus Estimates
09/17/2001 2:22 PM
Biovail Board Approves Stock-Repurchase Program
09/06/2001 8:23 AM
Biovail Reports Positive Tramadol Extended Release Clinical Results
08/27/2001 8:35 AM
Biovail Completes Cardizem XL NDA Filing
07/31/2001 7:45 AM
Biovail Reports Record Second Quarter 2001 Results
07/30/2001 8:45 AM
Biovail Announces Second Quarter 2001 Earnings Release Date
07/24/2001 8:46 AM
Biovail Reports Positive Cardizem XL Clinical Results
07/10/2001 7:33 AM
Biovail and Celgene Announce d-methylphenidate Filing in Canada
06/18/2001 12:00 AM
Study in the Lancet reports results of combination therapy of ReoPro(R) and Retavase(R) (half-dose) for heart attack treatment
05/11/2001 8:05 AM
Biovail Included in Toronto Stock Exchange --TSE-- 35 Index; Listing to Commence May 11, 2001
04/26/2001 7:35 AM
Biovail Reports Record First Quarter 2001 Financial Results
04/06/2001 4:05 PM
Court Dismisses Bayer's Patent Infringement Suit Against Biovail
03/07/2001 9:16 AM
Biovail Comments On Florida Court Hearing
02/28/2001 7:02 AM
Biovail Announces Record 2000 Fourth Quarter and Year End Financial Results; Revenue and Diluted Earnings per Share Increase 79% and 67% Respectively
02/14/2001 2:03 PM
Biovail Confirms Docket Posting of New Tiazac Patent in Orange Book
02/07/2001 8:05 AM
Biovail Announces Generic Procardia XL 30mg Final Approval, Teva to Launch Product Immediately
01/30/2001 8:55 AM
Biovail Confirms Tiazac Patent Listing in FDA Orange Book
01/03/2001 9:40 AM
Biovail Announces Filing of Three ANDA's; Generic Versions of Adalat CC 90mg, Procardia XL 90mg and Tegretol 400mg
01/02/2001 7:34 AM
Biovail Acquires Cardizem Product Lines From Aventis; To Expand U.S. Sales Force to 800; Launch of New Diltiazem Formulation - Cardizem XL - Expected Early 2002
12/29/2000 5:58 PM
Biovail to Host Conference Call to Discuss Significant Product Line Acquisition; Call To Be Held Tuesday, January 2, 2001 at 8:15 a.m.
12/05/2000 7:35 AM
Biovail Receives Adalat CC Final Approval; Marketing Partner Teva To Launch Immediately
11/01/2000 12:46 PM
Biovail Added to S&P / Toronto Stock Exchange - TSE - 60 Index, Listing to Commence November 2, 2000
10/26/2000 7:09 AM
Biovail Reports Record Third Quarter Financial Results; Diluted EPS Increases 69% to $0.27 - Excluding Charges
10/04/2000 7:37 AM
Biovail to Acquire DJ Pharma for $212.5 Million; Establishing a Significant US Sales and Marketing Capability; Transaction to be Accretive to Earnings Per Share
09/28/2000 7:39 AM
Biovail Receives Procardia XL Final Approval; Marketing Partner Teva Launching Immediately; Biovail Also Announces a 2-1 Stock Split
09/19/2000 7:35 AM
Biovail Initiates Tramadol Phase III Clinical Trials
07/27/2000 7:19 AM
Biovail Reports Record Second Quarter Financial Results
07/25/2000 8:53 AM
Biovail's Generic Procardia XL Tentatively Approved by the FDA
06/29/2000 7:30 AM
Biovail Completes Development of New Celexa Formulation; Lundbeck to Initiate Phase III Studies
05/30/2000 7:31 AM
Biovail Announces Senior Executive Appointments
04/27/2000 7:10 AM
Biovail Reports Record 2000 First Quarter Financial Results
04/07/2000 8:03 AM
Biovail Announces Launch of First Commercial Product Using Patented FlashDose Technology
03/23/2000 8:35 AM
Biovail Announces the Completion of its Concurrent Common Share and Convertible Subordinated Preferred Equivalent Debenture Offerings and its Cash Tender Offer for Senior Notes
03/17/2000 12:50 PM
Biovail Completes Concurrent Offerings
03/13/2000 7:30 AM
Biovail Announces FDA Final Approval of Generic Adalat CC 30mg; Teva to Launch Product Immediately
03/08/2000 7:30 AM
Biovail Announces Its Appeal to District Court Decisions
03/07/2000 7:30 AM
Biovail Receives Majority of Consents in Connection With Debt Tender Offer
03/06/2000 8:38 AM
Biovail Receives FDA Approval for Novel Once Daily Diltiazem Formulation - New Drug Application Optioned to Forest Laboratories
03/01/2000 4:44 PM
Biovail Announces Public Offerings
02/24/2000 7:17 AM
Biovail Reports Record 1999 Fourth Quarter and Year-End Financial Results
02/17/2000 7:51 AM
Biovail Receives Final Approval for Voltaren XR Generic - Marketing Partner Teva Launching Immediately -
02/11/2000 8:02 AM
Biovail Acquires Ampligen Marketing Rights for Canada; New Treatment for Chronic Fatigue Syndrome
02/07/2000 8:50 AM
Biovail to Acquire Significant Manufacturing Facilities in Puerto Rico; To Expand Other Sites in Virginia and Manitoba
02/04/2000 7:59 AM
Biovail Initiates Buspirone Clinical Trials
01/19/2000 12:00 AM
Biovail Divests Irish Manufacturing Operations
01/06/2000 10:42 AM
Biovail Shareholders Approve All Proposed Resolutions
12/23/1999 3:27 PM
Biovail Receives Final Approval for Generic Cardizem CD; Marketing Partner Teva Launching Immediately
12/22/1999 10:37 AM
Biovail Announces Proposed Stock Split and the Expiration of Biovail Technologies Ltd.'s Offer to Purchase Its Outstanding 7% Convertible Subordinated Debentures
12/01/1999 4:02 PM
Biovail Announces Purchase of Generic Version of Procardia XL From Intelligent Polymers
11/17/1999 7:32 AM
Biovail Announces Offer to Purchase All of the Outstanding 7% Convertible Subordinated Debentures of Biovail Technologies Ltd. - Formerly Fuisz Technologies Ltd.
11/16/1999 1:18 PM
Biovail Included in Toronto Stock Exchange - TSE - 100 Index; Listing to Commence November 17, 1998
11/12/1999 1:26 PM
Biovail / Fuisz Merger Approved
11/12/1999 8:04 AM
Biovail Stock Split Approved by Board of Directors - Convening a Special Shareholder Meeting to Approve a 2-For-1 Stock Split
11/10/1999 7:34 AM
Biovail Announces Average Share Price and Expected Exchange Ratio for Fuisz Technologies Ltd. Acquisition
10/28/1999 7:04 AM
Biovail Reports Record 1999 Third Quarter and Year to Date Financial Results
10/25/1999 1:55 PM
Sale of Fuisz European Subsidiaries; German, French and Italian Units Sold to Shire
10/25/1999 7:05 AM
Biovail Receives Generic Cardizem CD Tentative Approval
10/20/1999 5:15 PM
Biovail Completes Public Offering of 5,000,000 Shares
10/15/1999 2:23 PM
Biovail Completes Share Offering
10/14/1999 7:13 AM
Biovail and Elan Sign Generic Adalat CC Agreement; Biovail to Accelerate Launch of Adalat CC'S 30mg Dosage
09/21/1999 8:08 PM
Biovail Announces Public Offering - In Canada and The United States
09/03/1999 8:01 AM
Biovail and Fuisz Announce Results of Tender Offer
08/27/1999 4:37 PM
Biovail Announces Expiration of Tender Offer for Fuisz Technologies Ltd.
08/19/1999 12:00 AM
Biovail Obtains Bondholder Consent for its Acquisition of Additional Fuisz Shares
07/28/1999 12:00 AM
Biovail Reports Record 1999 Second Quarter and Year to Date Financial Results
07/26/1999 12:00 AM
Biovail to Acquire Fuisz Technologies; Acquisition to Expand Biovail's Pipeline of Products and Delivery Platforms
07/02/1999 12:00 AM
Biovail Acquires Exclusive Rights to Market Spectral's Cardiac STATus-TM in Canada
06/30/1999 12:00 AM
Biovail Receives Generic Adalat CC Tentative Approval
05/19/1999 12:00 AM
Biovail and Mylan Sign Generic Verelan Co-Marketing Agreement -- Product Being Shipped Immediately
05/06/1999 12:00 AM
Biovail Corporation International Today Announced
04/28/1999 12:00 AM
Biovail Reports Record 1999 First Quarter Financial Results
03/04/1999 12:00 AM
Biovail Receives Brexidol Marketing Approval In Canada
02/10/1999 12:00 AM
Celexa Approved in Canada
01/19/1999 12:00 AM
Biovail and Lundbeck Sign Agreements On Celexa; Biovail to Develop Controlled Release Citalopram for Worldwide Markets; Companies to Co-Promote Celexa in Canada
01/05/1999 12:00 AM
Biovail's Tiazac(R) Receives Ontario Formulary Approval
11/17/1998 12:00 AM
CLARIFICATION of BW1847, BIOVAIL- CORPORATION from Nov. 16
09/15/1998 12:00 AM
Biovail To Market Centocor's Retavase In Canada
08/17/1998 12:00 AM
Biovail Announces Stock-Repurchase Program
07/28/1998 12:00 AM
Biovail Reports Record 1998 Second Quarter Financial Results
|
|
|
